Selected Publications of Laboratory Endocrinology

2023

Korbut AI, Romanov VV, Klimontov VV. Urinary markers of tubular injury and renal fibrosis in patients with type 2 diabetes and different phenotypes of chronic kidney disease.Life 2023; 13(2):343. doi: 10.3390/life13020343.

2022

Fazullina O.N., Korbut A.I., Klimontov V.V. Factors associated with trabecular bone score in postmenopausal women with type 2 diabetes and normal bone mineral density. World J. Diabetes. 2022;13(7):553-565. doi: 10.4239/wjd.v13.i7.553.

Rossing P., Burgess E., Agarwal R., Anker S.D., Filippatos G., Pitt B., Ruilope L.M., Gillard P., MacIsaac R.J., Wainstein J., Joseph A., Brinker M., Roessig L., Scott C., Bakris G.L.; FIDELIO-DKD Investigators. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care. 2022;45(4):888-897. doi: 10.2337/dc21-1944.

Klimontov V.V., Semenova J.F. Glucose variability in subjects with normal glucose tolerance: Relations with body composition, insulin secretion and sensitivity. Diabetes Metab Syndr. 2022;16(1):102387. doi: 10.1016/j.dsx.2022.102387.

Klimontov V., Kladov D., Berikov V., Semenova J. Nocturnal glucose fluctuations in patients with type 1 diabetes: which patterns are associated with hypoglycemia? Diabetes Technology and Therapeutics. 2022; 24 (Suppl. 1): A-164. doi: 10.1089/dia.2022.2525.abstracts.

Klimontov V., Semenova J., Korbut A.Factors affecting glucose variability in patients with type 1 diabetes in the hospital setting. Diabetes Technology and Therapeutics. 2022; 24 (Suppl. 1): A-199. doi: 10.1089/dia.2022.2525.abstracts.

Saik O.V., Klimontov V.V. 1291-P: Bioinformatics Analysis of Gene Networks Associated with Glucose Variability and Inflammatory Pathways in Diabetes. Diabetes 2022; 71 (Suppl. 1): P-1091. doi.org/10.2337/db22-1291-P.

-

Klimontov VV, Semenova JF. Glucose variability in subjects with normal glucose tolerance: Relations with body composition, insulin secretion and sensitivity. Diab Metab Syndr. 2022;16(1):102387. doi: 10.1016/j.dsx.2022.102387.

2021

Klimontov V.V., Koroleva E.A., Khapaev R.S., Korbut A.I., Lykov A.P. Carotid Artery Disease in Subjects with Type 2 Diabetes: Risk Factors and Biomarkers. J Clin Med. 2021;11(1):72. doi: 10.3390/jcm11010072.

Saik O.V., Klimontov V.V. Hypoglycemia, Vascular Disease and Cognitive Dysfunction in Diabetes: Insights from Text Mining-Based Reconstruction and Bioinformatics Analysis of the Gene Networks. Int J Mol. Sci. 2021; 22: Article 12419. doi: 10.3390/ijms222212419.

Klimontov V.V., Saik O.V., Korbut A.I. Glucose Variability: How Does It Work? Int J Mol Sci. 2021; 22; Article 7783. doi: 10.3390/ijms22157783.

Klimontov V., Semenova J.F., Korbut A.I. 135-OR: Impaired Awareness of Hypoglycemia Is Associated with Residual Beta-Cell Function and Glucose Variability Parameters in Patients with Type 1 Diabetes. Diabetes 2021; 70(1): 135-OR. – doi: 10.2337/db21-135-OR.

Berikov V., Semenova J.F., Klimontov V. 340-P: Nocturnal Hypoglycemia Prediction in Hospitalized Patients with Type 1 Diabetes Using Combined Supervised and Unsupervised Ensemble Learning. Diabetes 2021; 70(1): 340-P. doi: 10.2337/db21-340-P.

Saik O.V., Klimontov V. 384-P: Text Mining and Bioinformatic Identification of Genes Linking Glycemic Variability and Impaired Angiogenesis in Diabetes. Diabetes 2021; 70; (1): 384-P. – doi: 10.2337/db21-384-P.

Saik O., Klimontov V. Bioinformatic analysis by ANDSystem revealedmembers of IL-6 signaling pathway initiated by glucose variability andinvolved in diabetic retinopathy. In: 2021 IEEE Ural-Siberian Conference onComputational Technologies in Cognitive Science, Genomics and Biomedicine(CSGB) 2021; P: 30-32. – doi: 10.1109/CSGB53040.2021.9496018.

Berikov VB, Kozinetz RM, Semenova JF, Klimontov VV. Machine learning approaches for prediction of nocturnal hypoglycaemia in patients with type 1 diabetes in a hospital setting. Diabetologia 2021; 64(Suppl. 1): 84-85.

Klimontov VV,Dashkin MV, Semenova JF. Continuous glucose monitoring parameters are related to serum levels of non-enzymatic glycation products in patients with type 1 diabetes. Diabetologia 2021; 64(Suppl. 1): 330.

2020

Korbut AI, Taskaeva IS, Bgatova NP, Muraleva NA, Orlov NB, Dashkin MV, Khotskina AS, Zavyalov EL, Konenkov VI, Klein T, Klimontov VV. SGLT2 Inhibitor Empagliflozin and DPP4 Inhibitor Linagliptin Reactivate Glomerular Autophagy in db/db Mice, a Model of Type 2 Diabetes. Int J Mol Sci. 2020; 21(8): 2987. doi: 10.3390/ijms21082987.

Spiryova D, Vorobev A, Klimontov V, Koroleva E, Moskalenskiy A. Optical activation of single platelets reveals the early calcium dynamics. Biomed Opt Express. 2020; 11 (3): 3319-3330. doi: 10.1364/BOE.392745

Korbut AI, Orlov NB, Fazullina ON, Klimontov VV. 2149-PUB: The Changes in the Panel of Circulating Cytokines Associated with Chronic Kidney Disease in Patients with Type 2 Diabetes. Diabetes 2020; 69 (S1). doi: org/10.2337/db20-2149-PUB.

2019

Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Nowack C, Kolkhof P, Ferreira AC, Schloemer P, Filippatos G; on behalf of the FIDELIO-DKD study investigators; FIDELIO-DKD study investigators.Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.Am J Nephrol.2019;50(5):333-344. doi: 10.1159/000503713.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC68888...

Ruilope LM, Agarwal R, Anker SD, Bakris GL, Filippatos G, Nowack C, Kolkhof P, Joseph A, Mentenich N, Pitt B; FIGARO-DKD study investigators.Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. Am J Nephrol.2019;50(5):345-356. doi: 10.1159/000503712 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC68899...

Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Melnick JZ, Miller MG, Pergola PE, Perkovic V, Tobe S, Yi T, Wigderson M, de Zeeuw D; SONAR Committees and Investigators. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet 2019; 393(10184): 1937-1947. doi: 10.1016/S0140-6736(19)30772-X.

Korbut AI, Klimontov VV, Orlov NB, Khotskina AS, Zav'yalov EL. Relationships between Body Composition and Plasma Levels of Pancreatic, Gut, and Adipose Tissue Hormones in db/db Mice, a Model of Type 2 Diabetes Mellitus. Bull Exp Biol Med. 2019;167(3):325-328. doi: 10.1007/s10517-019-04519-8.

Baranova AV, Klimontov VV, Letyagin AY, Orlov YuL. Medical genomics research at BGRS-2018. BMC Medical Genomics 2019;12(S2):36. doi: 10.1186/s12920-019-0480-0.

Korbut AI, Vinogradov IV, Klimontov VV. Clinical phenotypes and biomarkers of non-albuminuric and albuminuric patterns of chronic kidney disease in subjects with type 2 diabetes. Diabetologia 2019; 62 (S.1): S479.

Koroleva EA, Khapaev RS, Lykov AP, Klimontov VV. Serum levels of calponin 1, relaxin and l-citrulline in subjects with type 2 diabetes: the relationships with carotid atherosclerosis parameters. Diabetologia 2019; 62 (S1): S517.

Korbut AI, Klimontov VV, Vinogradov IV, Romanov VV. Risk factors and urinary biomarkers of non-albuminuric and albuminuric chronic kidney disease in patients with type 2 diabetes. World J Diabetes. 2019; 10(11): 517-523. doi: 10.4239/wjd.v10.i11.517.

Michurina SV, Cherepanova MA, Ishchenko IY, Arkhipov SA, Klimontov VV, Zav'yalov EL. Effect of Linagliptin on the Ratio of Apoptosis Regulators in the Model of Non-Alcoholic Fatty Liver Disease in db/db Mice. Bull Exp Biol Med. 2019; 167(2): 210-214. doi: 10.1007/s10517-019-04493-1.

Korbut AI, Klimontov VV. Clinical Features and Biomarkers of Nonalbuminuric and Albuminuric Patterns of Chronic Kidney Disease in Subjects with Type 2 Diabetes. Diabetes. 2019; 68 (S.1): 2233-PUB. doi: 10.2337/db19-2233-PUB

Klimontov VV, Korbut AI. Albuminuric and non-albuminuric patterns of chronic kidney disease in type 2 diabetes. Diabetes Metab Syndr. 2019; 13 (1): 474-479. doi: 10.1016/j.dsx.2018.11.014

2018

Myakina NE, Lotz IJu, Klimontov VV. Continuous Glucose Monitoring Data Analysis in Insulin-Treated Type 1 And Type 2 Diabetic Subjects with the Use of Original Software. / Processings of 11th International Multiconference Bioinformatics of Genome Regulation and Structure / System Biology and Biomedicine (BGRS/SB). Novosibirsk, 2018. – P. 24-27. doi: 10.1109/CSGB.2018.8544878.

Voytko M, Pospelova TI, Klimontov VV, Fazullina ON. Bone mineral density changes in patients with Hodgkin's lymphoma. / Processings of 11th International Multiconference Bioinformatics of Genome Regulation and Structure / System Biology (BGRS/SB). Novosibirsk, 2018. – P. 18-19. doi: 10.1109/CSGB.2018.8544777.

Korbut A, Klimontov V, Taskaeva Ju, Bgatova N, Zavjalov E. Empagliflozin and linagliptin ameliorate podocyte injury and enhance autophagy in a model of type 2 diabetic nephropathy. / Processings of 11th International Multiconference Bioinformatics of Genome Regulation and Structure / System Biology (BGRS/SB). Novosibirsk, 2018. – P. 28-32. doi: 10.1109/CSGB.2018.8544785.

Bulumbaeva DM, Klimontov VV, Bgatova NP, Taskaeva JuS, Fazullina ON, Orlov NB, Konenkov VI, Soluyanov MYu, Savchenko SV. Serum Levels of Adipokines in Type 2 Diabetic Subjects: the Relationships with Adipose Tissue Distribution and Microvasculature. / Processings of 11th International Multiconference Bioinformatics of Genome Regulation and Structure / System Biology (BGRS/SB). Novosibirsk, 2018. – P. 81-84. doi: 10.1109/CSGB.2018.8544862.

Klimontov VV, Bulumbaeva DM, Lykov AP, Fazullina ON, Bgatova NP, Orlov NB, Pfeiffer AFHP, Pivovarova O, Rudovich N. Serum levels of WISP1/CCN4 in subjects with type 2 diabetes: the relationships with body fat distribution and adipose tissue dysfunction. / Processings of 11th International Multiconference Bioinformatics of Genome Regulation and Structure / System Biology (BGRS/SB). Novosibirsk, 2018. – P. 85-87. doi: 10.1109/CSGB.2018.8544817.

Klimontov VV, Koroleva EA, Fazullina ON. Switching to insulin glargine 300 U/mL from other basal insulin analogues provides less 24-hour glucose variability in hospitalized patients with type 1 diabetes / Processings of 11th International Multiconference Bioinformatics of Genome Regulation and Structure / System Biology (BGRS/SB). Novosibirsk, 2018. – P. 100-101. doi: 10.1109/CSGB.2018.8544728.

Klimontov VV. Impaired hypoglycemia awareness in diabetes: epidemiology, mechanisms and therapeutic approaches. Diabetes Mellitus. 2018; 21 (6): 513-523. doi: 10.14341/dm9597

Fazullina ON, Klimontov VV, Konenkov VI, Shevchenko AV, Prokofiev VF, Tsepilov YA. Associations of polymorphisms in the gene promoters of cytokines and matrix metalloproteinases with bone mineral density in postmenopausal type 2 diabetic women. Diabetes Mellitus. 2018;21(1):26-33. doi: 10.14341/DM8825.

Klimontov V.V., Bulumbaeva D.M., Bgatova N.P., Gavrilova Yu.S., Fazullina O.N., Orlov N.B., Korbut A.I., Savchenko S.V., Konenkov V.I. The relationships between serum levels of adipokines, body fat distribution and subcutaneous microvasculature in type 2 diabetic subjects. // Diabetes. – 2018. – Vol. 67, Suppl. 1. – P. A539. doi: 10.2337/db18-2055-P.

Korbut A.I., Klimontov V.V., Gavrilova Yu.S., Bgatova N.P., Ischenko I.Yu., Zavjalov E.L. Empagliflozin and Linagliptin Alleviate Glomerular Changes in a Model of Diabetic Nephropathy. // Diabetes. – 2018. – Vol. 67, Suppl. 1. – P. A135. doi: 10.2337/db18-511-P.

Mauricio D., Meneghini L., Orsi E., Klimontov V., Westerbacka J., Melas-Melt L., Pilorge V., Perfett R., Khunti K. Change in Insulin Dose and HbA1c by Geographical Region: Results from the Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) Study. // Diabetes. – 2018. – Vol. 67, Suppl. 1. – P. A274. doi: 10.2337/db18-1037-P.

Klimontov VV, Lazarev MM, Makhotin AA, Letyagin AJ, Anisimova LA, Bulumbaeva DM, Koroleva EA, Lykov AP. Insulin-induced lipohypertrophy: clinical and ultrasound characteristics. Diabetes mellitus. 2018; 21 (4): 255-263. doi: 10.14341/dm9549

Klimontov VV, Korbut AI. Normoalbuminuric chronic kidney disease in diabetes. Ter Arkh. 2018; 90 (10): 94-98. Russian. doi: 10.26442/terarkh2018901094-98.

Lazarev MM, Klimontov VV, Makhotin AA, Bulumbaeva DM, Koroleva EA, Letyagin AY. Quantitative ultrasound characteristics of insulin-induced lipohypertrophy in subjects with diabetes. Diabetologia. 2018; 61 (Suppl. 1): S125. doi: 10.1007/s00125-018-4693-0

Klimontov VV, Bulumbaeva DM, Lykov AP, Fazullina ON, Bgatova NP, Pfeiffer AFH, Pivovarova O, Rudovich N. Circulating WISP1/CCN4 is associated with body fat distribution and adipose tissue dysfunction in subjects with type 2 diabetes. Diabetologia. 2018; 61 (Suppl. 1): S257. doi: 10.1007/s00125-018-4693-0

Korbut AI, Klimontov VV, Taskayeva YuS, Bgatova NP, Zav’yalov EL. Empagliflozin and linagliptin alleviate podocyte injury and activate glomerular autophagy in a model of type 2 diabetes. Diabetologia. 2018; 61 (Suppl. 1): S510. doi: 10.1007/s00125-018-4693-0

Klimontov VV. Impact of Glycemic Variability on Cardiovascular Risk in Diabetes. Kardiologiia 2018; (10): 80-87. doi: 10.18087/cardio.2018.10.10152

2017

Korbut AI, Klimontov VV. Empagliflozin: a new strategy for nephroprotection in diabetes. Diabetes Mellitus 2017; 20 (1): 75-84.doi: 10.14341/DM8005

Klimontov V.V., Myakina N.E. Glucose variability indices predict the episodes of nocturnal hypoglycemia in elderly type 2 diabetic patients treated with insulin. // Diabetes Metab. Syndr. 2017. – Vol. 11, N. 2. – P. 119-124. doi: 10.1016/j.dsx.2016.08.023.

Klimontov VV, Tyan NV, Orlov NB, Shevchenko AV, Prokofiev VF, Myakina NE, Bulumbaeva DM, Konenkov VI. Association of serum levels and gene polymorphism of vascular endothelium growth factor with coronary artery disease in type 2 diabetic patients. Kardiologiia. 2017; 57 (5): 17-22. Russian. doi: 10.18565/cardio.2017.5.17-22.

Michurina SV, Ishchenko IY, Arkhipov SA, Klimontov VV, Rachkovskaya LN, Konenkov VI, Zavyalov EL. Effects of Melatonin, Aluminum Oxide, and Polymethylsiloxane Complex on the Expression of LYVE-1 in the Liver of Mice with Obesity and Type 2 Diabetes Mellitus. Bull Exp Biol Med. 2016; 162 (2): 269-272.

Bulumbaeva DM, Klimontov VV, Tyan NV, Orlov NB, Konenkov VI. Serum levels of angiogenic growth factors in subjects with type 2 diabetes with and without peripheral artery disease. Diabetologia. 2017; 60 (Suppl. 1): S526. doi: 10.1007/s00125-017-4350-z.

Korbut AI, Klimontov VV, Bgatova NP, Gavrilova YS, Ischenko IY, Orlov NB, Dozenko AS, Zavjalov EI. Linagliptin alleviates podocyte injury and enhances glomerular nephrin expression in a model of type 2 diabetes. Diabetologia. 2017; 60 (Suppl. 1): S550. doi: 10.1007/s00125-017-4350-z.

Fazullina ON, Klimontov VV, Konenkov VI, Shevchenko AV, Prokofiev VF, Tsepilov YA. Modeling the risk of osteopenia and osteoporosis in postmenopausal women with type 2 diabetes on the sets of clinical and immunogenetic parameters. 2017 International MultiConference on Engineering, Computer and Information Sciences (SIBIRCON). Novosibirsk, Russia, 18-24 September 2017.

Klimontov V, Korbut A, Fazullina O, Bulumbaeva D, Orlov N. Ghrelin deficiency is associated with obesity, adipose tissue dysfunction and glucose variability in type 2 diabetes. IDF Diabetes Congress 2017, Abu Dhabi, UAE, 4-8 December 2017

Klimontov VV, Shevchenko AV, Tyan NV, Bulumbaeva DM, Prokof'ev VF, Konenkov VI. Polymorphisms in Genes of Cytokines and Matrix Metalloproteinases Associated with Ischemic Heart Disease in Patients With Type 2 Diabetes. Kardiologiia. 2017; 57(8): 5-10. doi: 10.18087/cardio.2017.8.10011

Klimontov VV. Insulin Glargine 300 U/ml: New Opportunities for the Management of Glycemic Variability in Patients with Diabetes. Effective Pharmacotherapy. Endocrinology. 2017; 39: 32-38.

2016

1. Lingvay I, Manghi FP, García-Hernández P, Norwood P, Lehmann L, Tarp-Johansen MJ, Buse JB; DUAL V Investigators. Effect of insulin glargine up-titration vs insulin degludec/liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes: the DUAL V randomized clinical trial. JAMA. 2016;315(9):898-907. doi: 10.1001/jama.2016.1252.

2. Korbut AI, Klimontov VV. Incretin-based therapy: renal effects. Diabetes Mellitus.2016;19(1):53-63. Russian. doi: 10.14341/DM7727.

3. Klimontov VV, Myakina NE, Tyan NV. Heart rate variability is associated with interstitial glucose fluctuations in type 2 diabetic women treated with insulin. SpringerPlus 2016;5:337. doi: 10.1186/s40064-016-1932-z.

4. Klimontov VV, Tyan NV, Orlov NB, Shevchenko AV. Serum levels of VEGF family angiogenic factors and VEGF-A gene polymorphism are associated with coronary artery disease in type 2 diabetic patients. Diabetes 2016; 65: A109.
5. Klimontov VV, Shevchenko AV, Tyan NV. Serum levels and genetic variants of inflammatory cytokines are associated with coronary artery disease in type 2 diabetic subjects. Diabetes 2016; 65: A113-114.
6. Klimontov VV, Tyan NV, Lykov AP, Bondarenko NA, Myakina NE. Lack of association between production of cytokines, NO, and MMP-9 by peripheral blood mononuclear cells and glycemic variability in type 2 diabetic patient. Diabetes 2016; 65: A436.

7. Ovsyannikova AK, Rymar OD, Shakhtshneider EV, Klimontov VV, Koroleva EA, Myakina NE, Voevoda MI. ABCC8-Related Maturity-onset diabetes of the young (MODY12): clinical features and treatment perspective. Diabetes Ther. 2016; 7(3): 591-600. doi: 10.1007/s13300-016-0192-9.

8. Klimontov VV, Tyan NV, Bulumbaeva DM, Orlov NB, Konenkov VI. Serum levels of angiogenic regulators in type 2 diabetic patients: the relationships with cardiovascular complications. Diabetologia. 2016; 59 (S1): S539.

9. Tyan NV, Klimontov VV, Shevchenko AV, Fazullina ON, Orlov NB, Konenkov VI. Polymorphisms in the gene promoters of IL4, IL6, IL10 and TNFA associated with serum levels of cytokines in type 2 diabetic subjects. Diabetologia. 2016; 59 (S1): S513.

10. Klimontov VV, Tyan NV, Fazullina ON, Myakina NE, Lykov AP, Konenkov VI. Clinical and metabolic factors associated with chronic low-grade inflammation in type 2 diabetic patients. Diabetes Mellitus. 2016; 19 (4): 295-302. Russian. doi: doi: 10.14341/DM7928.

11. Michurina S.V., Ischenko I.Ju., Klimontov V.V., Archipov S.A., Myakina N.E., Cherepanova M.A., Zavjalov E.L., Koncevaya G.V., Konenkov V.I. Linagliptin alleviates fatty liver disease in diabetic db/db mice. // World J. Diabetes. – 2016. – Vol. 7, N. 19. – P. 534-546. doi: 10.4239/wjd.v7.i19.534.

12.Klimontov VV, Fazullina ON, Lykov AP, Konenkov VI. The relationships between bone turnover markers and bone mineral density in postmenopausal type 2 diabetic women. Diabetes mellitus. 2016; 19 (5): 375-382. doi: 10.14341/DM8008

2015

1. Klimontov VV, Fazullina ON. The relationship of total body composition with bone mineral density in postmenopausal women with type 2 diabetes. Diabetes Mellitus 2015;18(1):65-69. doi: 10.14341/DM2015165-69.

2. Klimontov VV, Eremenko NV, Myakina NE, Fazullina ON. Cystatin C and collagen type IV in diagnostics of chronic kidney disease in type 2 diabetic patients. Diabetes Mellitus. 2015;18(1): 87-93. Russian. doi: 10.14341/DM2015187-93.

3. Klimontov VV, Bgatova NP, Gavrilova JuS, Ischenko IJu, Myakina NE, Michurina SV, Zavjalov EL. Linagliptin allieviate renal injury in a model of type 2 diabetic nephropathy. Diabetes.2015;64(S.1):A144.

4. Myakina NE, Klimontov VV, Safarov DM. Glucose fluctuations аnd heart rate variability in tуре 2 diabetic patients: The Results of simultaneous glucose and ECG monitoring. Diabetes2015;64(S.1):A166.

5. Klimontov VV, Myakina NE, Tyan NV, Romanov VV. Elevated levels of circulating macrophage-related inflammatory cytokines in tуре 2 diabetic patients with chronic kidney disease. Diabetes. 2015;64(S.1):A614-A615.

6. Konenkov VI, Klimontov VV, Myakina NE, Tian NV, Fazullina ON, Romanov VV. Increased serum concentrations of inflammatory cytokines in type 2 diabetic patients with chronic kidney disease. Ter Arkh. 2015;87(6):45-49. Russian. doi: 10.17116/terarkh201587645-49. WOS:000358823600008

7. Myakina NE, Klimontov VV. Nocturnal hypoglycemia can be predicted by retrospective analysis of glucose variability in elderly type 2 diabetic patients treated by insulin. Diabetologia.2015;58(S.1):S416.

8. Klimontov VV, Myakina NE, Tyan NV. Systemic inflammation and glucose variability in type 2 diabetic patients with and without chronic kidney disease. Diabetologia.2015;58(S.1):S544.

9. Klimontov VV, Myakina NE. The relationships between glucose variability and renal function in type 2 diabetes patients on basal-bolus insulin therapy. Diabetes Mellitus. 2015;18(4):66-71. doi: 10.14341/DM7181.

2014

1. Konenkov VI, Klimontov VV. Gene and cell-based technologies for the treatment of diabetic foot syndrome. Diabetes Mellitus 2014;17(1):63-69. doi: 10.14341/DM2014163-69.

2. Klimontov VV, Tsiberkin AI, Fazullina ON, Prudnikova MA, Tyan NV, Konenkov VI. Hypoglycemia in type 2 diabetes patients treated with insulin: the advantages of continuous glucose monitoring. Diabetes Mellitus. 2014;17(1):75-80. Russian. doi: 10.14341/DM2014175-80.

3. Konenkov VI, Klimontov VV, Kuznetsova IV. Impaired angiogenesis and lymphangiogenesis in diabetes mellitus. Arkh Patol. 2014;76(2):55-59. Review.

4. Klimontov VV, Myakina NE. Glycaemic variability in diabetes: a tool for assessing the quality of glycaemic control and the risk of complications. Diabetes Mellitus. 2014;17(2):18-24. doi: 10.14341/DM20142.

5. Klimontov VV, Myakina NE. Insulin glargine: Pharmacokinetic and pharmacodynamic basis of clinical effect. Diabetes Mellitus 2014;17(4):99-107. doi: 10.14341/DM2014499-107.

2013

1. Konenkov VI, Klimontov VV, Michurina SV, Prudnikova MA, Ishenko IJ. Melatonin and diabetes: from pathophysiology to the treatment perspectives. Diabetes Mellitus. 2013;16(2):11-16. doi: 10.14341/2072-0351-3751.

2. Klimontov VV, Tsiberkin AI, Fazullina ON, Prudnikova MA, Tyan NV, Konenkov VI. Glucose variability and hypoglycaemic excursions in elderly type 2 diabetic patients treated with insulin. Diabetologia.2013;56(S.1):S239.

3. Konenkov VI, Klimontov VV, Chernykh VV, Tjan NV. Anti-VEGF agents in the treatment of diabetic macular edema. Diabetes Mellitus. 2013;16(4):78-84. Russian. doi: 10.14341/DM2013478-84.

2012

1.Konenkov VI, Shevchenko AV, Prokof'ev VF, Klimontov VV, Korolev MA, Fazullina ON, Lapsina SA, Koroleva EA. Associations of vascular endothelial growth factor (VEGF) gene and cytokine (IL-1B, IL-4, IL-6, IL-10, TNFA) genes combinations with type 2 diabetes mellitus in women. Diabetes Mellitus. 2012;15(3):4-10. doi: org/10.14341/2072-0351-6079. web:

2. Konenkov VI, Klimontov VV. Vasculogenesis and angiogenesis in diabetes mellitus: novel pathogenetic concepts for treatment of vascular complications. Diabetes Mellitus. 2012; 15(4): 17-27. doi: 10.14341/2072-0351-5533